💥 Fed cuts sparks mid cap boom! ProPicks AI scores with 4 stocks +23% each. Get October’s update first.Pick Stocks with AI

Non-animal models poised to fuel $1.5 billion surge in Australian medical sector

Published 07/09/2023, 01:58 pm
Updated 07/09/2023, 02:30 pm
© Reuters.  Non-animal models poised to fuel $1.5 billion surge in Australian medical sector

A report by CSIRO reveals a $1.5 billion growth potential in non-animal models, outlining a strategic pathway for Australia to solidify its role in advancing medical product development.

The report offers 10 key recommendations to fast-track Australia's progress in demonstration, scaling and commercialisation of these models.

Internationally, there’s been sharp growth in the non-animal testing market – which stood at US$1.11 billion in 2019 – as shifts in policy discourage animal testing.

The CSIRO report highlights Australia's unique advantages, stating, "Australia has comparative global strengths in non‑animal models for several organ systems likely to disrupt the status quo about the use of animal models over the next 15 years … including existing infrastructure, high throughput screening capabilities and internationally recognised capacity for induced pluripotent stem cell generation, a key input for non-animal model development.

“These emerging models will also be critical to protect and further strengthen Australia’s $1.4 billion clinical trials sector.”

Non-animal models outperform traditional models

The report also outlined the flexibility and cost-effectiveness of non-animal models, stating: “The complexity of non-animal models is rapidly increasing, equating to or surpassing the performance of traditionally used animal models in several applications.

“Due to their enhanced biological relevance, non-animal models can increase productivity and reduce costs by identifying unsuitable medical products earlier in development and re-investing savings in more promising candidates.

“These models also support broader global ‘3Rs’ objectives to replace, reduce and refine the use of animals for research and testing purposes.”

An expert panel discussion will take place at the AusBiotech 2023 conference, featuring speakers from St Vincent’s Hospital Melbourne, Tessara Therapeutics and CSIRO Futures.

The panel aims to investigate evolving methods in drug screening, thereby heralding a new era of effective therapies.

You can register for AusBiotech 2023 for more information and read CSIRO's full report here.

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.